Skip to content
LATEST
Health

South Korea Permits Personal Import of Foreign-Prescribed Obesity Medications

South Korea has legalized the personal carry-on import of foreign-prescribed obesity drugs, a move expected to impact domestic market demand due to…

South Korea Permits Personal Import of Foreign-Prescribed Obesity Medications

Effective November 12, South Korean authorities have authorized the personal carry-on import of obesity medications, including Wegovy and Mounjaro, provided they are legally prescribed and purchased abroad. This policy shift reverses previous restrictions that classified these drugs as hazardous, which had led to widespread customs seizures of medications brought in by travelers. Under the new guidelines, individuals may bring up to six vials of these medications into the country, with provisions for larger quantities up to a three-month supply if medically justified.

The regulatory change follows a significant increase in unauthorized attempts to import these drugs, particularly from Japan. Customs data indicates that the number of intercepted obesity medication shipments rose from one case in 2024 to over 1,000 cases in the first eight months of 2026. A substantial majority of these seizures originated from Japan, highlighting a growing trend of medical tourism driven by significant price disparities between the two markets.

Market analysis reveals that the cost of Mounjaro in Japan is approximately one-third of the price in South Korea. In Japan, Mounjaro is covered by health insurance system, allowing the government to regulate pricing, which was recently reduced by 25% to ensure sustainability. Conversely, in South Korea, the drug is not currently covered by national health insurance, and manufacturers maintain autonomy over pricing. Negotiations between the manufacturer and health insurance provider regarding reimbursement status remain ongoing following a previous breakdown in talks.

While the new policy facilitates personal carry-on imports, the government maintains a strict prohibition on direct online purchases of these medications from overseas. Authorities emphasize that customs officials will verify the authenticity of the products at the border. This regulatory adjustment aims to balance the needs of patients seeking affordable treatment with the necessity of preventing the influx of counterfeit pharmaceuticals and the potential for medication misuse. Policymakers should monitor whether this policy leads to a further surge in medical tourism to Japan and its subsequent impact on the domestic pharmaceutical market and local pricing strategies.

More stories

Latest news